Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment when a stem cell transplant is unsuitable (terminated appraisal)

  • Technology appraisal
  • TA1083
  • Published: 

History

Documents created during the development process.

Notes